List of Excipients in Branded Drug EVISTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	EVISTA	raloxifene hydrochloride	0002-4184	ANHYDROUS LACTOSE
Eli Lilly and Company	EVISTA	raloxifene hydrochloride	0002-4184	BUTYL ALCOHOL
Eli Lilly and Company	EVISTA	raloxifene hydrochloride	0002-4184	CARNAUBA WAX

EVISTA (Raloxifene) Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Evista, the branded raloxifene hydrochloride tablet, has limited conventional patent protection and no biosimilar barrier. Its commercial value is therefore concentrated in low-cost generic manufacturing, differentiated oral delivery, combination products, improved tolerability, and lifecycle management. The most practical formulation strategy is a robust immediate-release tablet that matches the reference product’s dissolution and bioequivalence profile while controlling lactose, lubricant, disintegrant, and coating variability.

What is Evista and how is it regulated?

Evista contains raloxifene hydrochloride, a selective estrogen receptor modulator. The FDA approved Evista in 1997 for the prevention and treatment of postmenopausal osteoporosis and later approved it to reduce the risk of invasive breast cancer in certain postmenopausal women at increased risk.[1]

Attribute	Evista
Active ingredient	Raloxifene hydrochloride
Strength	60 mg tablet
Dosage form	Oral, film-coated immediate-release tablet
Original sponsor	Eli Lilly and Company
FDA approval	1997
Key indications	Postmenopausal osteoporosis; reduction of invasive breast-cancer risk
Drug class	Selective estrogen receptor modulator
Biosimilar pathway	Not applicable; raloxifene is a small molecule
Primary regulatory pathway for generics	ANDA under section 505(j)
Reformulation pathway	Potentially 505(b)(2), depending on the proposed change

Raloxifene is administered once daily without regard to meals. The reference product’s labeling states that food does not materially alter systemic exposure in a way that requires meal-based dosing instructions.[1]

What excipients are used in Evista tablets?

Evista uses a conventional solid-oral formulation. Public labeling identifies inactive ingredients that support powder flow, tablet compaction, disintegration, lubrication, and film coating.[1]

The formulation strategy can be summarized as follows:

Functional role	Reference-product excipient category	Commercial purpose
Diluent	Lactose-based excipient	Provides tablet mass and compressibility
Binder or granulation aid	Povidone or related polymer	Supports granule strength and content uniformity
Disintegrant	Crospovidone	Promotes tablet breakup and dissolution
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film coating	Hypromellose-based coating system, with color and plasticizer components	Improves appearance, handling, swallowability, and stability

The exact qualitative and quantitative composition of a generic product does not need to duplicate Evista. An ANDA applicant must establish pharmaceutical equivalence and bioequivalence, not excipient identity.

Which excipients create the greatest formulation risk?

The principal development risks are raloxifene’s low aqueous solubility, dose uniformity at a 60 mg strength, lubricant sensitivity, and dissolution performance after scale-up.

Raloxifene is practically insoluble in water. The active ingredient’s dissolution can be affected by:

• Particle-size distribution and surface area
• Crystal form and milling conditions
• Wetting behavior
• Granulation endpoint
• Disintegrant level and distribution
• Magnesium stearate concentration and blending time
• Compression force and tablet porosity
• Film-coating weight gain

Magnesium stearate is a particular process variable. Excessive lubrication or prolonged blending can create hydrophobic particle surfaces and slow dissolution. A generic manufacturer seeking a narrow process window should control lubricant addition time, blend speed, and compression force through design-of-experiments work.

Crospovidone is commercially attractive because it supports rapid tablet disintegration without requiring a large formulation load. The developer must still demonstrate that the disintegrant remains effective after compression and does not produce excessive friability or capping.

Lactose-based diluents support low-cost manufacturing, but lactose intolerance claims, excipient labeling preferences, and supply-chain considerations create opportunities for lactose-free versions using microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed excipients.

What formulation patents protect Evista?

The original raloxifene composition and therapeutic-use patents were filed decades ago. Core composition-of-matter and primary method-of-use protection has expired in the United States. Evista is therefore primarily a legacy generic product rather than an active patent-protected brand.

Protection category	Current commercial significance
Raloxifene composition patents	Expired
Original osteoporosis indication	Expired regulatory and patent exclusivity
Breast-cancer risk-reduction indication	Expired exclusivity
Immediate-release tablet formulation	Limited protection; legacy patents are generally expired
New controlled-release formulation	Potentially patentable if technically differentiated
New salt, crystal form, or particle-size control	Potentially patentable if novel and non-obvious
Fixed-dose combination	Potentially patentable as a composition and method of use
Manufacturing process	Potentially patentable if it produces a measurable quality or stability advantage

The Orange Book is the controlling source for current FDA-listed patents and exclusivity. A current Orange Book review should distinguish between expired patents, withdrawn listings, and any patent information associated with specific approved products.[2]

Are there active Orange Book barriers to generic raloxifene?

No durable exclusivity barrier remains comparable to the original Evista market position. Raloxifene is available as an approved generic product in the United States, and the product is not protected by biologic reference-product exclusivity.

The commercial relevance of any residual Orange Book listing is therefore narrow. A generic applicant must address applicable listed patents through certification, but the principal market question is manufacturing cost and product quality rather than a fundamental patent blockade.

When did Evista lose exclusivity?

Evista lost its commercially meaningful exclusivity after expiration of the original patent and regulatory exclusivity period. The key timing milestones were:

Milestone	Timing
FDA approval for osteoporosis	1997
FDA approval for breast-cancer risk reduction	1999
First-wave patent and regulatory exclusivity period	Expired years ago
Generic raloxifene availability	Established
Current status	Mature, multisource generic market

The exact entry date for each generic depends on ANDA approval, litigation outcomes, settlement terms, and launch decisions. Those issues were relevant when the listed patents were still enforceable. They are no longer the principal determinant of market access.

Which companies are challenging Evista with Paragraph IV filings?

Paragraph IV risk was historically relevant to raloxifene because ANDA applicants could challenge listed Evista patents before expiry. Today, the commercial significance of a new Paragraph IV filing is limited because the central patent estate has aged beyond its effective protection period.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. It can trigger patent litigation under the Hatch-Waxman framework and a potential 30-month stay of FDA approval.[3] For raloxifene, the strategic value of such a filing would depend on whether a currently listed patent covers a specific formulation, indication, or product presentation.

Generic sponsors that compete in raloxifene are more likely to focus on abbreviated approval, manufacturing economics, and supply reliability than on litigation-driven market entry.

What commercial opportunities exist for raloxifene excipients?

1. Low-cost immediate-release tablets

The largest opportunity is a reliable, low-cost 60 mg tablet. The product can use widely available excipients and standard high-speed compression equipment. Value is created through:

• High drug-loading efficiency
• Short blending and granulation cycles
• Low tablet weight
• Strong content uniformity
• Fast dissolution across pH conditions
• Low friability and low capping rate
• Stable film coating at low weight gain

A formulation that reduces process variability can have greater commercial value than one using expensive specialty excipients.

2. Lactose-free or patient-preference formulations

A lactose-free version could address institutional purchasing requirements and patient preferences. Suitable alternatives include microcrystalline cellulose, mannitol, dibasic calcium phosphate, and co-processed diluents.

The commercial benefit is likely incremental rather than transformational. The product would need to retain equivalent dissolution, acceptable tablet size, and competitive manufacturing cost.

3. Solubility-enhanced formulations

Raloxifene’s low water solubility creates an opportunity for:

• Amorphous solid dispersions
• Nanocrystal or micronized-drug formulations
• Surfactant-assisted tablets
• Cyclodextrin complexes
• Lipid-based delivery systems
• Spray-dried dispersions
• Co-precipitated polymer systems

These approaches may improve dissolution or reduce exposure variability. They also increase development complexity, analytical burden, and manufacturing cost. A solubility-enhanced product has a stronger commercial case if it delivers a measurable clinical or pharmacokinetic benefit rather than only faster in vitro dissolution.

4. Modified-release products

A sustained-release raloxifene product could target reduced peak concentrations, improved tolerability, or less frequent dosing. The opportunity is technically more difficult because raloxifene is already dosed once daily.

A modified-release product would require evidence that the new exposure profile improves a clinically relevant outcome. A formulation patent alone would not guarantee market adoption. The developer would also face a new regulatory and reimbursement assessment.

5. Fixed-dose combinations

Raloxifene could be evaluated in combination with agents used in postmenopausal bone-health management. Potential combinations include calcium, vitamin D, or other osteoporosis therapies. Commercial viability depends on compatibility, pill burden, dosing alignment, and whether the combination improves adherence.

A fixed-dose product would likely require a 505(b)(2) or new-drug strategy rather than a simple ANDA if the combination or labeling differs materially from the reference product.

What manufacturing and intellectual-property barriers remain?

The strongest barriers are process and regulatory rather than foundational patent rights.

Manufacturing barriers

Key manufacturing controls include:

1. Active-ingredient particle-size control
2. Uniform distribution of raloxifene in the blend
3. Lubrication control
4. Compression-force management
5. Dissolution consistency after scale-up
6. Film-coating uniformity
7. Stability under heat and humidity
8. Control of polymorphic or solid-state behavior

A manufacturer that develops a robust direct-compression formulation may gain a cost advantage. A wet-granulation process may improve uniformity but increase capital use, cycle time, and residual-moisture risk.

Intellectual-property barriers

Potentially protectable innovations include:

• A specific solid form
• A particle-size distribution linked to dissolution performance
• A novel excipient combination
• A controlled-release matrix
• A solubility-enhancing dispersion
• A new combination product
• A manufacturing process that reduces impurities or improves stability
• A new clinical use outside the original approved indications

Method-of-use claims must be separated from the approved osteoporosis and breast-cancer risk-reduction indications. A new indication could support patent protection, but it would require clinical evidence and a regulatory pathway capable of supporting the proposed labeling.

How does Evista compare with competing osteoporosis drugs?

Product category	Active ingredient	Formulation barrier	Generic or biosimilar pressure	Commercial position
Evista	Raloxifene	Low for conventional tablet; higher for novel delivery	High generic pressure	Mature oral SERM market
Oral bisphosphonates	Alendronate, risedronate, ibandronate	Manufacturing and tolerability issues	High generic pressure	Large established class
Denosumab	Denosumab	Biologic manufacturing and interchangeability	Biosimilar pressure	Higher administration and reimbursement complexity
Teriparatide products	Teriparatide	Peptide delivery and device requirements	Biosimilar and follow-on pressure	Injectable, higher technical barrier
Romosozumab	Romosozumab	Biologic and device requirements	Lower near-term biosimilar exposure than small molecules	Specialty and higher-cost segment

Raloxifene’s advantages are oral dosing, low product complexity, and established clinical use. Its disadvantages include mature generic competition and class-specific safety restrictions, including venous thromboembolic risk described in the FDA label.[1]

What generic launch risks exist for raloxifene?

Generic launch risk is moderate from a technical perspective and high from a pricing perspective.

Risk	Assessment
Patent blocking	Low
ANDA pathway complexity	Moderate
Bioequivalence risk	Moderate
Dissolution failure risk	Moderate
Excipient supply risk	Low to moderate
Price erosion	High
Market-size risk	Moderate to high
Differentiated formulation opportunity	Moderate
Biosimilar competition	Not applicable

The most credible launch model is a conventional 60 mg tablet with a cost-efficient process and multiple qualified suppliers. A specialty excipient strategy is justified only when it solves a documented issue such as dissolution variability, stability, tablet size, or excipient exclusion.

What licensing deals and partnership models are available?

The most realistic partnership models are:

• Contract development and manufacturing for generic raloxifene
• Licensing of a solubility-enhanced formulation
• Regional commercialization rights
• Co-development of a fixed-dose combination
• Licensing of a controlled-release platform
• Supply agreements for co-processed excipients or specialty polymers

A licensing transaction based solely on expired Evista formulation claims would have limited value. A stronger deal would combine formulation know-how, comparative pharmacokinetic data, scalable manufacturing, and defensible patent claims.

Key Takeaways

• Evista is a 60 mg immediate-release raloxifene hydrochloride tablet.
• Its original patent and regulatory exclusivity have expired.
• No biosimilar pathway applies because raloxifene is a small molecule.
• Conventional generic tablets have the clearest commercial opportunity.
• Crospovidone, lactose-based diluents, povidone, magnesium stearate, and film-coating polymers support a low-cost formulation strategy.
• The main technical risks are solubility, dissolution, lubrication, particle size, and scale-up control.
• The strongest lifecycle opportunities are lactose-free products, solubility-enhanced systems, modified-release tablets, and fixed-dose combinations.
• Patent value now depends on new formulation, manufacturing, solid-form, or method-of-use claims rather than the legacy Evista estate.
• Pricing pressure is likely to exceed patent risk in the mature generic market.

FAQs

Is raloxifene suitable for a 505(b)(2) reformulation?

Yes. A materially different delivery system, new dosage form, or new clinical use could support a 505(b)(2) strategy if the applicant can rely partly on FDA findings for raloxifene while supplying new data.

Can a generic raloxifene manufacturer use different excipients from Evista?

Yes. The generic product does not need to copy the reference formulation. It must meet applicable pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements.

Does raloxifene have biosimilar competition?

No. Raloxifene is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, principally ANDAs, rather than biosimilar applications.

Is a raloxifene extended-release tablet commercially attractive?

Potentially, but the burden is high because the reference product already uses once-daily dosing. A modified-release product would need a clear clinical, tolerability, adherence, or pharmacokinetic advantage.

What is the most defensible new patent position for raloxifene?

The strongest prospects are usually a well-defined solid form, a reproducible solubility-enhanced formulation, a clinically meaningful modified-release system, a validated manufacturing process, or a new approved method of use.

References

1. U.S. Food and Drug Administration. (2020). Evista (raloxifene hydrochloride) tablets: Prescribing information. Eli Lilly and Company.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity when multiple first applicants are eligible for 180-day exclusivity. https://www.fda.gov/
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/